temazepam RESTORIL

Class: Benzodiazepine/​3-Hydroxy
FDA Indications: Insomnia
Off-Label Use: Anxiety, Periodic Limb Movement Disorder
Prescribing
FDA Schedule IV
Forms: 7.5, 15, 22.5, 30mg capsule
Dose Range: 15-45 mg/day
Starting: 15 to 30 mg at bedtime; some patients may respond to 7.5 mg in transient insomnia
Stopping: Rebound insomnia may occur 1-2 nights after stopping; if taken for more than a few weeks, taper

NAMI drug fact sheet

Precautions
Contraindications: Sleep apnea
Serious Side Effects: Overdose can result in hypotension, respiratory depression, and coma
Side Effects: sedation/somnolence, dizziness, confusion, disequilibrium, ataxia, lightheadedness, weakness, decreased libido, dysarthria, constipation, increased appetite, weight gain
Pharmacodynamics
1° MOA: GABAAR PAM
Target: GABAA: α1, α3, γ2, β3 (high); α2 (moderate)
Pharmacokinetics
t½: 11 (8-20)° TMAX: 2-3°
Absorption Rate: Medium
Lipid Solubility: Low-moderate
Substrate of: Conjugation
Inhibits: ∅ ; Induces:
Active Metabolites:
DDIs
  • - CNS depression with combined use of opioids
  • - estrogen containing oral contraceptives may accelerate its metabolism
Misc
  • - delays but doesn't ↓ REM
  • - one the 3 L-O-T benzodiazepines that only undergoes Phase II metabolism
  • - delayed aborption may benefit patients with middle-insomnia
Special Populations

Category X—↑ risk of oral cleft by 0.01%, use just before delivery associated with floppy infant syndrome, 3rd trimester use can cause withdrawal in newborns

Low incidence of infant toxicity and AEs associated with use during breastfeeding

Recommended initial dosage is 7.5 mg


There are no dosage adjustments provided in the manufacturer's labeling

There are no dosage adjustments provided in the manufacturer's labeling

logo

Developed & Designed by Kevin M. Nasky, D.O. • Built with Bootstrap, PHP & MySQL • Hosted by SiteGround
Last updated January 22 2018 19:18:05. Disclaimer: This website does not provide medical advice, nor is it a substitute for clinical judgment.